Drug intelligence / Profile preview

GLB-004

Development stage: Preclinical
Lead developer: GluBio Therapeutics
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

GLB-004 is a highly selective small-molecule therapeutic developed as a molecular glue degrader. It is being investigated for the treatment of renal cell carcinoma and other neoplasms. The drug acts by inducing proteolysis, specifically targeting disease-relevant proteins for degradation via the ubiquitin-proteasome system. GLB-004 is currently in preclinical or lead optimization stages, with its primary indication being renal cell carcinoma[1][2][4].

Other names: GLB-004GLB004GLB 004

Beyond the preview

Go deeper on GLB-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLB-004.

Explore the full profile